Joel E. Tepper

ORCID: 0000-0002-8591-4228
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Colorectal Cancer Surgical Treatments
  • Colorectal and Anal Carcinomas
  • Advanced Radiotherapy Techniques
  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • Pancreatic and Hepatic Oncology Research
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Radiation Therapy and Dosimetry
  • Sarcoma Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Esophageal Cancer Research and Treatment
  • Colorectal Cancer Screening and Detection
  • Advances in Oncology and Radiotherapy
  • Lung Cancer Treatments and Mutations
  • Effects of Radiation Exposure
  • Head and Neck Cancer Studies
  • Management of metastatic bone disease
  • Medical Imaging Techniques and Applications
  • Radiomics and Machine Learning in Medical Imaging
  • Vascular Tumors and Angiosarcomas
  • Lung Cancer Diagnosis and Treatment
  • Genetic factors in colorectal cancer
  • Esophageal and GI Pathology
  • Neuroendocrine Tumor Research Advances
  • Lung Cancer Research Studies

University of North Carolina at Chapel Hill
2016-2025

Carolina Institute for NanoMedicine
2016-2025

Inserm
2025

Centre de recherche en Epidémiologie et Santé des Populations
2025

Université Paris-Saclay
2025

UNC Lineberger Comprehensive Cancer Center
2014-2024

Aptiv (United States)
2024

University of North Carolina Hospitals
1992-2024

University of North Carolina Health Care
1994-2021

John Wiley & Sons (United States)
2018

Benjamin J. Raphael Ralph H. Hruban Andrew J. Aguirre Richard A. Moffitt Jen Jen Yeh and 95 more Chip Stewart A. Gordon Robertson Andrew D. Cherniack Manaswi Gupta Gad Getz Stacey Gabriel Matthew Meyerson Carrie Cibulskis Suzanne S. Fei Toshinori Hinoue Hui Shen Peter W. Laird Shiyun Ling Yiling Lu Gordon B. Mills Rehan Akbani Phillipe Loher Eric Londin Isidore Rigoutsos Aristeidis G. Telonis Ewan A. Gibb Anna Goldenberg Aziz M. Mezlini Katherine A. Hoadley Eric A. Collisson Eric S. Lander Bradley A. Murray Julian M. Hess Mara Rosenberg Louis Bergelson Hailei Zhang Juok Cho Grace Tiao Jaegil Kim Dimitri Livitz Ignaty Leshchiner Brendan Reardon Eliezer M. Van Allen Atanas Kamburov Rameen Beroukhim Gordon Saksena Steven E. Schumacher Michael S. Noble David I. Heiman Nils Gehlenborg Jaegil Kim Michael S. Lawrence Volkan Adsay Gloria M. Petersen David S. Klimstra Nabeel Bardeesy Mark D.M. Leiserson Reanne Bowlby L. Sylvia İnanç Birol Karen Mungall Sara Sadeghi John N. Weinstein Paul T. Spellman Yuexin Liu Laufey T. Ámundadóttir Joel E. Tepper Aatur D. Singhi Rajiv Dhir Paul Drwiega Thomas C. Smyrk Lizhi Zhang Paula Kim Jay Bowen Jessica Frick Julie M. Gastier‐Foster Mark Gerken Kevin Lau Kristen Leraas Tara M. Lichtenberg Nilsa C. Ramirez Jeremy Renkel Mark E. Sherman Lisa Wise Peggy Yena Erik Zmuda Juliann Shih Adrian Ally Miruna Balasundaram Rebecca Carlsen Andy Chu Eric Chuah Amanda Clarke Noreen Dhalla Robert A. Holt Steven J.M. Jones Darlene Lee Yussanne Ma Marco A. Marra Michael Mayo

10.1016/j.ccell.2017.07.007 article EN cc-by-nc-nd Cancer Cell 2017-08-01

The primary treatment modality for patients with carcinoma of the esophagus or gastroesophageal junction has been surgery, although radiation therapy concurrent chemotherapy produces similar results. As both have curative potential, there great interest in use trimodality therapy. To this end, we compared survival, response, and patterns failure to esophagectomy alone nonmetastatic esophageal cancer.Four hundred seventy-five eligible were planned enrollment. Patients randomly assigned either...

10.1200/jco.2007.12.9593 article EN Journal of Clinical Oncology 2008-02-28

ROSENBERG, STEVEN A. M.D., PH.D.; TEPPER, JOEL M.D.; GLATSTEIN, ELI COSTA, JOSE BAKER, ALAN BRENNAM, MURRAY DEMOSS, ERNEST V. SEIPP, CLAUDIA R.N.; SINDELAR, WILLIAM F. SUGARBAKER, PAUL WESLEY, ROBERT PH.D. Author Information

10.1097/00000658-198209000-00009 article EN Annals of Surgery 1982-09-01

We postulated that the pathologic evaluation of lymph nodes surgical specimens from patients with rectal cancer can have a substantial impact on time to relapse and survival.We analyzed data 1,664 T3, T4, or node-positive treated in national intergroup trial adjuvant therapy chemotherapy radiation therapy. Associations between number found by pathologist specimen survival outcomes were investigated.Patients divided into groups nodal status corresponding quartiles numbers examined. The...

10.1200/jco.2001.19.1.157 article EN Journal of Clinical Oncology 2001-01-01

To determine survival and relapse rates by T N stage treatment method in five randomized phase III North American rectal adjuvant studies.Data were pooled from 3,791 eligible patients enrolled onto Central Cancer Treatment Group (NCCTG) 79-47-51, NCCTG 86-47-51, US Gastrointestinal Intergroup 0114, National Surgical Adjuvant Breast Bowel Project (NSABP) R01, NSABP R02. Surgery alone (S) was the arm 179 patients. The remaining received as follows: irradiation (RT) (n = 281), RT + fluorouracil...

10.1200/jco.2004.08.173 article EN Journal of Clinical Oncology 2004-04-06

Hepatocelluar carcinoma (HCC) is the most common primary malignancy of liver in adults and third cause cancer death worldwide. The incidence HCC United States rising steadily because prevalence hepatitis C viral infection other causes hepatic cirrhosis. majority patients have underlying dysfunction, which complicates patient management search for safe effective therapies. Clinical Trials Planning Meeting (CTPM) was convened by National Cancer Institute's Gastrointestinal Steering Committee...

10.1200/jco.2010.28.7805 article EN Journal of Clinical Oncology 2010-08-03

Context Pelvic fractures, including hip are a major source of morbidity and mortality in older women.Although therapeutic pelvic irradiation could increase the risk such this effect has not been studied. ObjectiveTo determine if women who undergo for malignancies (anal, cervical, or rectal cancers) have higher rate fracture than with do irradiation. Design, Setting, ParticipantsWe conducted retrospective cohort study using Surveillance, Epidemiology, End Results (SEER) cancer registry data...

10.1001/jama.294.20.2587 article EN JAMA 2005-11-22

A retrospective study was done of all patients who were seen for definitive treatment adenocarcinoma the pancreas at Massachusetts General Hospital from 1963 to 1973. There a total 145 patients. Thirty-one treated with radical surgery, 16% operative mortality, 5-year crude survival rate 15%, and local recurrence 50%. Sixty-two palliative procedure 5%. Fifty-two biopsy alone, no survivors. In addition, there 35 did not have surgical performed only because extent disease. It is proposed that...

10.1002/1097-0142(197603)37:3<1519::aid-cncr2820370340>3.0.co;2-o article EN Cancer 1976-03-01

Neuroendocrine tumors (NETs) arise from a variety of anatomic sites and share the capacity for production hormones vasoactive peptides. Because their perceived rarity, NETs have not historically been focus rigorous clinical research. However, diagnosed incidence has increasing, estimated prevalence in United States exceeds 100,000 individuals. The recent completion several phase III studies, including those evaluating octreotide, sunitinib, everolimus, demonstrated that evaluation novel...

10.1200/jco.2010.33.2056 article EN Journal of Clinical Oncology 2011-01-25

PURPOSE: The gastrointestinal Intergroup studied postoperative adjuvant chemotherapy and radiation therapy in patients with T3/4 N+ rectal cancer after potentially curative surgery to try improve determine the risk of systemic local failure. PATIENTS AND METHODS: All had a surgical resection were treated two cycles followed by chemoradiation additional chemotherapy. Chemotherapy regimens bolus fluorouracil (5-FU), 5-FU leucovorin, levamisole, 5-FU, levamisole. Pelvic irradiation was given...

10.1200/jco.2002.07.132 article EN Journal of Clinical Oncology 2002-04-01

To study the relationship between body mass index (BMI) and rates of sphincter-preserving operations, overall survival, cancer recurrence, treatment-related toxicities in patients with rectal cancer.We evaluated a nested cohort 1,688 stage II III participating randomized trial postoperative fluorouracil-based chemotherapy radiation therapy.Obese were more likely to undergo an abdominoperineal resection (APR) than normal-weight (odds ratio, 1.77; 95% CI, 1.27 2.46). When analyzed by sex,...

10.1200/jco.2004.07.121 article EN Journal of Clinical Oncology 2004-02-14

PURPOSE The combination of radiation therapy with fluorouracil (5-FU)-based chemotherapy is generally accepted as appropriate postoperative for patients adenocarcinomas the rectum that extend through bowel wall or lymph nodes positive tumor. We attempted to determine whether efficacy this could be improved by addition leucovorin and/or levamisole. METHODS A total 1,696 were randomized and eligible treatment one four schemes. All received two cycles bolus 5-FU-based systemic followed pelvic...

10.1200/jco.1997.15.5.2030 article EN Journal of Clinical Oncology 1997-05-01

During the period 1971 to 1985, 220 patients with soft tissue sarcoma of extremities, torso, and head-neck region were managed by radiation resectional surgery at Massachusetts General Hospital (MGH). Actuarial 5-year local control disease-free survival rates 86% 70%, respectively. The success rate improved during this time period. Namely, for 1975, 1976 1980, 1981 1985 81%, 94%, For same periods, 64%, 76%. One hundred thirty-one treated postoperative radiation, 89 preoperative radiation. In...

10.1200/jco.1988.6.5.854 article EN Journal of Clinical Oncology 1988-05-01

WILLETT, CHRISTOPHER G. M.D.; TEPPER, JOEL E. COHEN, ALFRED M. ORLOW, ERICA B.A.; WELCH, CLAUDE M.D. Author Information

10.1097/00000658-198412000-00001 article EN Annals of Surgery 1984-12-01

PURPOSE: To determine the maximum-tolerated dose, dose-limiting toxicities, and potential antitumor activity of twice-weekly gemcitabine concurrent radiation in patients with locally advanced pancreatic cancer. PATIENTS AND METHODS: Nineteen histologically confirmed adenocarcinoma pancreas were studied at Wake Forest University Baptist Medical Center North Carolina Chapel Hill. The initial dose was 20 mg/m 2 by 30-minute intravenous infusion each Monday Thursday for 5 weeks 50.4 Gy to...

10.1200/jco.1999.17.7.2208 article EN Journal of Clinical Oncology 1999-07-01
Coming Soon ...